• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»chlamydia

Can Europe contain its STI surge before antimicrobial resistance narrows treatment options?

By Pallavi Madhiraju on May 24, 2026   Medical Devices & Diagnostics  

Can Europe contain its STI surge before antimicrobial resistance narrows treatment options?

Europe’s STI surge is testing diagnostics, prevention and treatment capacity as gonorrhoea and syphilis reach record levels.

Labcorp and Quest partner with Visby to expand access to rapid at-home PCR STI test

By Pallavi Madhiraju on January 11, 2026   Medical Devices & Diagnostics  

Labcorp and Quest partner with Visby to expand access to rapid at-home PCR STI test

Visby’s at-home PCR STI test now on Quest and Labcorp. Find out how this redefines women’s health diagnostics and access. Read the full analysis.

Recent Posts

  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
  • Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
  • Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
  • Why Multi Radiance Medical’s MR5 ACTIV PRO clearance matters for tendon pain treatment
  • Entyvio pediatric filing puts Takeda at the centre of the next IBD treatment debate
  • Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset
  • Vertanical’s Exilby approval puts cannabis-derived pain drugs under a brighter spotlight
  • Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes